Alagille Syndrome Market: How Is Maralixibat Transforming the...

blog ekledi Botanik

2026-05-12 10:13:49

Alagille Syndrome Market: How Is Maralixibat Transforming the Treatment Landscape for Cholestatic Liver Disease?

Maralixibat's commercial approval — the ileal bile acid transporter (IBAT) inhibitor approved by the FDA in 2021 (Livmarli, Mirum Pharmaceuticals) for cholestatic pruritus in Alagille syndrome patients aged five and older representing the first disease-specific pharmacological approval in this rare pediatric condition — marks a watershed commercial and clinical moment, with the...

0 Yorumlar 0 Paylaşımlar 16 Görüntülenme 0 İncelemeler